Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma

Next Previous
Trial Profile

A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PHP 201 (Primary)
  • Indications Low tension glaucoma
  • Focus Therapeutic Use
  • Sponsors pH Pharma

Most Recent Events

  • 01 Mar 2022 Primary endpoint has been met (Mean diurnal IOP change from baseline at post-treatment time point of 4 weeks- PHP-201 0.5%), as per Results published in the Acta Ophthalmologica
  • 01 Mar 2022 Primary endpoint has been met (Mean diurnal IOP change from baseline at post-treatment time point of 4 weeks - PHP-201 0.25%), as per Results published in the Acta Ophthalmologica
  • 01 Mar 2022 Results published in the Acta Ophthalmologica

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top